333 Bay St, Suite 2400, Bay Adelaide Ctr, Box 20, Toronto, ON
Year called to bar: 2000 (ON)
Stuart Brotman is Leader of the firm's Insolvency and Restructuring Group. Acting in all nature of insolvency proceedings, Stuart assists clients in bankruptcy, receivership and restructuring under the Companies' Creditors Arrangement Act, the Bankruptcy and Insolvency Act, the Canada Business Corporations Act and the Winding Up and Restructuring Act. Stuart has considerable cross-border experience, having advised clients under the CCAA and Chapter 15 of the United States Bankruptcy Code. Advising both private and public companies, these clients include a broad range of stakeholders, including debtors, creditors, suppliers, customers and other contracting parties and monitors, receivers and trustees in bankruptcy. He also frequently represents prospective purchasers in pursuing and completing asset sales in domestic and cross-border insolvency proceedings.
Concordia International Corp. (“Concordia” or the “Company”) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, completed the recapitalization of approximately US$4 billion of secured and unsecured debt in September 2018 pursuant to a plan of arrangement (the “CBCA Plan”) under the Canada Business Corporations Act (“CBCA”).
On July 25, 2018, Wheaton Precious Metals Corp. (Wheaton), through its wholly-owned subsidiary Wheaton Precious Metals International Ltd. (Wheaton International), closed a gold and palladium streaming agreement with Sibanye Gold Limited (Sibanye).
Pacific West Commercial Corporation (Pacific West), an affiliate of Vancouver-based Stern Partners Inc. (Stern Partners), completed the acquisition of the business and assets of Comark Inc. (Comark). Financial terms were undisclosed.
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.